EANS-News: Epigenomics and QIAGEN Sign Collaboration Agreement in Colorectal Cancer Blood Testing
QIAGEN acquires options to mSEPT9 biomarker and DNA methylation technologies; QIAGEN granted license to pursue Septin9 product related R&D Contact: Dr. Achim Plum Sen. VP Corporate Development Epigenomics AG Tel: +49 30 24345 368 achim.plum@epigenomics.com Branche: Biotechnology ISIN: DE000A0BVT96 WKN: A0BVT9 Index: Prime All Share, Technology All Share Börsen: ...